Mesothelioma Management

Introduction to Mesothelioma

• Mesothelioma is a cancer affecting the lining of the lungs, typically related to asbestos exposure that occurred decades ago, and affects breathing, causing chest pain, with a median survival of approximately 6-18 months 1

Palliative Care Approach

• For elderly patients with mesothelioma, palliative care with symptom management should be the primary approach, as aggressive treatments offer limited benefit and increased toxicity in this age group, according to the American Society of Clinical Oncology 2, 3
• The British Thoracic Society guidelines recommend using prognostic scoring systems to estimate survival, including the LENT score for patients with malignant pleural effusion, which indicates high-risk patients have a median survival of only 44 days (22-77 days) 4

Performance Status and Treatment

• Patients with Poor Performance Status (PS ≥ 2) should receive single-agent palliative chemotherapy or palliative care alone, while those with Very Poor Performance Status (PS ≥ 3) should receive palliative care only, as recommended by the American Society of Clinical Oncology 2, 3
• Advanced age (85 years) is an independent negative prognostic factor, and each additional decade of age further reduces survival expectations in patients with mesothelioma 4

Symptom Management

• Dyspnea can be managed with low-dose oral morphine and oxygen (if oxygen saturation is reduced) 5
• Pain can be managed with palliative radiation therapy, with a recommended dose of 20 Gy in 5 fractions for localized chest pain 3
• Pleural Effusion can be managed with talc pleurodesis or indwelling pleural catheter 5

Supportive Care

• Psychological support through specialist nurses or support groups is recommended 5

Chemotherapy Options

• For selected patients with good PS (0-1) and minimal comorbidities, carboplatin may be substituted for cisplatin to reduce toxicity, as recommended by the American Society of Clinical Oncology 2, 3
• Single-agent chemotherapy may be considered for patients with PS 2 3

Treatment Considerations

• Radical surgery is contraindicated due to age and associated morbidity 1, 6
• Bevacizumab is not recommended for patients >75 years with cardiovascular comorbidities 2, 3
• Observation rather than immediate treatment may be considered for asymptomatic patients 3
• The presence of multiple serious comorbidities, such as advanced dementia, CAD, and prior AMI, dramatically reduces life expectancy 1
• Evidence of tumor growth and lymphangitic spread indicates aggressive disease, with limited treatment options due to age and comorbidities, resulting in a significantly shorter life expectancy, approximately 1-3 months, with a high likelihood of mortality due to respiratory failure from local disease progression 1
• The BTS decision tree classification would place a patient with similar characteristics in prognostic group 4, with a median survival of 5.68 months (3.12-10.84), although this must be adjusted downward due to advanced age and comorbidities 4